Home - Global Think-tank SLD

Key Pillars & Topics

Act on What Matters

Explore all the materials, classified under the three pillars of the Think-tank

Global Metabolic & Liver Health Policy

Metabolic & Liver Health Equity

Public Health & Clinical Best Practices

Discover our latest materials filtered by type:

Policy & insights

Events & roundtables

Topics & news

Annual strategy & reports

Events & roundtables categories

All

Flagship events

Webinars

Roundtables

Topics & news categories

All

News

Impact stories

Press releases

Coming soon!

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

Detecting at-risk steatotic liver disease and liver fibrosis in the community
Adams, L. A., Thiele, M., & Tsochatzis, E. A.

Hepatology ():10.1097/HEP.0000000000001400, May 16, 2025.

10.1097/HEP.0000000000001400
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

A global research priority agenda to advance public health responses to fatty liver disease
Lazarus, Jeffrey V. et al.

Journal of Hepatology, Volume 79, Issue 3, 618 - 634

http://doi.org/10.1016/j.jhep.2023.04.035
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

A global action agenda for turning the tide on fatty liver disease
Lazarus, Jeffrey V. et al.

Hepatology 79(2):p 502-523, February 2024.

10.1097/HEP.0000000000000545

See all

Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

MASLD/MASH in Spain: A liver health policy brief

See all

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

Chronic Liver Disease, MASLD/MASH, and the Global NCD Agenda

See all

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

Global Think-tank on Steatotic Liver Disease 2025 Meeting
Nedic, I., Brennan, P. N., Isaacs, S. D., Thiele, M., & Lazarus, J. V.

The Lancet Regional Health - Europe

10.1016/j.lanepe.2025.101366
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

The People-first Liver Charter
Lazarus, J.V., Ivancovsky Wajcman, D., Pannain, S. et al.

Nature Medicine

10.1038/s41591-025-03759-8
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
Duseja, Ajay et al.

Journal of Clinical and Experimental Hepatology, Volume 13, Issue 2, 273 - 302.

10.1016/j.jceh.2022.11.014

See all

Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
Boeckmans, Joost et al.

The Lancet Regional Health – Europe, Volume 48, 101153.

10. 1016/j.lanepe.2024. 101153
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Alkhouri, Naim et al.

Journal of Hepatology, Volume 82, Issue 3, 438 - 445.

10.1016/j.jhep.2024.08.031
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in Metabolic Dysfunction-Associated Steatotic Liver Disease
Alkhouri, Naim, et al.

Am J Gastroenterol. 2025 Mar 27.

10.14309/ajg.0000000000003432

See all

Metabolic & Liver Health Equity

Metabolic & Liver Health Equity

Isn’t it time the HealthyNYC campaign becomes more fit for purpose?
Author: Jeff Lazarus

See all

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

5-6 June 2025

Palau Macaya | Barcelona, Spain

In-person Flagship Gathering – Barcelona
Read more

See all

Metabolic & Liver Health Equity

Metabolic & Liver Health Equity

26/11/2024

Virtual

Prevention of liver disease in people living with obesity and/or diabetes [EN ESPAÑOL]
Read more

See all

Coming soon!

See all

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

26 June 2025

From Barcelona to the World: Global Think‑tank on Liver Disease Makes Headlines and Enters the Scientific Record
Read more
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

18 June 2025

The Global Think-tank on Steatotic Liver Disease Endorses the Global Metabolic Health Roundtable series: Advancing a Unified Voice for Action
Read more
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

5-6 June 2025

Barcelona Hosts Global Think-tank on Steatotic Liver Disease: A Collective Push for Global Action on MALSD/MASH
Read more

See all

Coming soon!

See all

Coming soon!

See all

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

Global Think-tank on Steatotic Liver Disease 2025 Meeting
Nedic, I., Brennan, P. N., Isaacs, S. D., Thiele, M., & Lazarus, J. V.

The Lancet Regional Health - Europe

10.1016/j.lanepe.2025.101366
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

The People-first Liver Charter
Lazarus, J.V., Ivancovsky Wajcman, D., Pannain, S. et al.

Nature Medicine

10.1038/s41591-025-03759-8
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Clinical utility of the Fibrosis-4 index for predicting mortality in patients with heart failure with or without metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
Boeckmans, Joost et al.

The Lancet Regional Health – Europe, Volume 48, 101153.

10. 1016/j.lanepe.2024. 101153
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Decreases in cT1 and liver fat content reflect treatment-induced histological improvements in MASH
Alkhouri, Naim et al.

Journal of Hepatology, Volume 82, Issue 3, 438 - 445.

10.1016/j.jhep.2024.08.031
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

ALADDIN: A Machine Learning Approach to Enhance the Prediction of Significant Fibrosis or Higher in Metabolic Dysfunction-Associated Steatotic Liver Disease
Alkhouri, Naim, et al.

Am J Gastroenterol. 2025 Mar 27.

10.14309/ajg.0000000000003432
Public Health & Clinical Best Practices

Public Health & Clinical Best Practices

Clinicopathological Profile and Outcome of a Large Cohort of Patients with Nonalcoholic Fatty Liver Disease from South Asia: Interim Results of the Indian Consortium on Nonalcoholic Fatty Liver Disease
Duseja, Ajay, et al.

Nature Reviews Gastroenterology & Hepatology volume 21, pages668–686 (2024).

10.1089/met.2021.0104

See all

Metabolic & Liver Health Equity

Metabolic & Liver Health Equity

26/11/2024

Virtual

Prevention of liver disease in people living with obesity and/or diabetes [EN ESPAÑOL]
Read more
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

5-6 June 2025

Palau Macaya | Barcelona, Spain

In-person Flagship Gathering – Barcelona
Read more

See all

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

26 June 2025

From Barcelona to the World: Global Think‑tank on Liver Disease Makes Headlines and Enters the Scientific Record
Read more
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

18 June 2025

The Global Think-tank on Steatotic Liver Disease Endorses the Global Metabolic Health Roundtable series: Advancing a Unified Voice for Action
Read more
Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

5-6 June 2025

Barcelona Hosts Global Think-tank on Steatotic Liver Disease: A Collective Push for Global Action on MALSD/MASH
Read more

See all

Featured Policy & Insights

Key documents and perspectives to support policy development, academic inquiry, and strategic action

Strategic pillars

Clinical practice guidelines & position papers

Latest Publications

Expert Commentary

UN General Assembly High-Level Meeting (HLM)

on the Prevention and Control of Noncommunicable Diseases (NCDs)

Chronic liver disease affects over 1.5 billion people worldwide, yet it remains largely absent from global NCD strategies. In September 2025, world leaders, policymakers, and health experts will come together at a global forum to address this growing health challenge.

All the details can be found here.

Latest News

A curated selection of articles, impact stories, and press releases

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

26 June 2025

26 June 2025

From Barcelona to the World: Global Think‑tank on Liver Disease Makes Headlines and Enters the Scientific Record
Read more

12 Next

Upcoming Events

Join our next webinars, conferences, and live sessions

Global Metabolic & Liver Health Policy

Global Metabolic & Liver Health Policy

5-6 June 2025

Palau Macaya | Barcelona, Spain

In-person Flagship Gathering – Barcelona
Read more

Check our events

Category	Early Bird (before 1 April)	On-site
Private Sector/Industry	495	695
Start-up*	150	200
Healthcare Professional, Academic, Public Health/Professional Association, NGO	100	150
Young Researcher / Trainee / PostDoc / Student / Young Person (under 25) *	50	50
Patient or Patient Representative *	50	50

Global Think-tank on Steatotic Liver Disease

Reframing liver disease. Advancing public health.

Connect

Discuss

Discuss

Engage

Key Pillars & Topics

Act on What Matters

In-person Flagship Gathering – Barcelona

Prevention of liver disease in people living with obesity and/or diabetes [EN ESPAÑOL]

Coming soon!

From Barcelona to the World: Global Think‑tank on Liver Disease Makes Headlines and Enters the Scientific Record

The Global Think-tank on Steatotic Liver Disease Endorses the Global Metabolic Health Roundtable series: Advancing a Unified Voice for Action

Barcelona Hosts Global Think-tank on Steatotic Liver Disease: A Collective Push for Global Action on MALSD/MASH

Coming soon!

Coming soon!

Prevention of liver disease in people living with obesity and/or diabetes [EN ESPAÑOL]

In-person Flagship Gathering – Barcelona

From Barcelona to the World: Global Think‑tank on Liver Disease Makes Headlines and Enters the Scientific Record

The Global Think-tank on Steatotic Liver Disease Endorses the Global Metabolic Health Roundtable series: Advancing a Unified Voice for Action

Barcelona Hosts Global Think-tank on Steatotic Liver Disease: A Collective Push for Global Action on MALSD/MASH

Featured Policy & Insights

Key documents and perspectives to support policy development, academic inquiry, and strategic action

UN General Assembly High-Level Meeting (HLM)

on the Prevention and Control of Noncommunicable Diseases (NCDs)

Latest News

A curated selection of articles, impact stories, and press releases

From Barcelona to the World: Global Think‑tank on Liver Disease Makes Headlines and Enters the Scientific Record

Upcoming Events

Join our next webinars, conferences, and live sessions

In-person Flagship Gathering – Barcelona

5. Strengthen the capacity of community health services to prevent and treat MASLD through social prescribing

5. Leverage electronic health records (EHR) through integrated automated diagnostic tools

4. Increase awareness and education of MASLD/MASH among at-risk groups and healthcare professionals

3. Add MASLD/MASH as an indicator to the list of Key Health System Indicators

2. Create a national MASLD registry, cohort, or observatory

1. Launch a Ministry of Health-led whole-of-government strategy

References

What is ALD?

What is MetALD?

What is MASLD?

What is steatotic liver disease?

Further reading

Registration fees

Criteria for start-ups:

What’s included in your ticket?

Agenda

5 June 2025

6 June 2025

*CARPA